Pharmaron Beijing Valuation
Is 3759 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3759 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3759 (HK$13.34) is trading below our estimate of fair value (HK$13.62)
Significantly Below Fair Value: 3759 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3759?
Key metric: As 3759 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 3759's PE Ratio? | |
|---|---|
| PE Ratio | 26x |
| Earnings | CN¥1.88b |
| Market Cap | CN¥44.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.1x |
| Enterprise Value/EBITDA | 20.6x |
| PEG Ratio | 4x |
Price to Earnings Ratio vs Peers
How does 3759's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.6x | ||
2269 WuXi Biologics (Cayman) | 21.8x | 17.6% | HK$61.6b |
2268 WuXi XDC Cayman | 51.7x | 27.1% | HK$33.0b |
1521 Frontage Holdings | 52.9x | 64.8% | HK$2.5b |
3320 China Resources Pharmaceutical Group | 8.1x | 7.3% | HK$33.0b |
3759 Pharmaron Beijing | 26x | 6.4% | HK$44.4b |
Price-To-Earnings vs Peers: 3759 is good value based on its Price-To-Earnings Ratio (26x) compared to the peer average (33.6x).
Price to Earnings Ratio vs Industry
How does 3759's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 3759 is good value based on its Price-To-Earnings Ratio (26x) compared to the Asian Life Sciences industry average (31.8x).
Price to Earnings Ratio vs Fair Ratio
What is 3759's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 26x |
| Fair PE Ratio | 12.8x |
Price-To-Earnings vs Fair Ratio: 3759 is expensive based on its Price-To-Earnings Ratio (26x) compared to the estimated Fair Price-To-Earnings Ratio (12.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Innovent Biologics
HK$63.1b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$38.55
7D
4.2%
1Y
-12.4%
3SBio
HK$13.5b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.72
7D
3.6%
1Y
-23.8%
United Laboratories International Holdings
HK$19.2b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$10.58
7D
7.4%
1Y
32.4%